Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | CSF1R | P07333 | 2/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909354 | 0.84 | ABCG2 (0.35) | ABCG2PDE5AMAPTCLK1CLK2 | |
| SCHEMBL29909881 | 0.83 | DYRK1A (0.35) | ABCG2PDE5AMAPTCSF1RCLK1 | |
| SCHEMBL29909353 | 0.82 | ABCG2 (0.37) | ABCG2PDE5AMAPTCLK1CLK2 | |
| SCHEMBL29909406 | 0.82 | ABCG2 (0.36) | ABCG2PDE5AMAPTEGFRDHODH | |
| SCHEMBL29909655 | 0.82 | ABCG2 (0.34) | ABCG2PDE5AMAPTALDH1A1CLK1 | |
| SCHEMBL29909118 | 0.81 | ABCG2 (0.36) | ABCG2PDE5ADHODH | |
| SCHEMBL29909643 | 0.80 | ABCG2 (0.37) | ABCG2PDE5AMAPTDHODH | |
| SCHEMBL29909024 | 0.80 | ABCG2 (0.37) | ABCG2PDE5AEGFRCSF1RDHODH | |
| SCHEMBL29909708 | 0.80 | ABCG2 (0.41) | ABCG2PDE5AMAPTKDM4EALDH1A1 | |
| SCHEMBL29909741 | 0.80 | NPC1 (0.43) | ABCG2PDE5AMAPTDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ABCG2 4216/4885PDE5A 1924/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.